Sanara Current Deferred Revenue from 2010 to 2024
| SMTI Stock | USD 37.70 0.38 1.02% |
Current Deferred Revenue | First Reported 2004-09-30 | Previous Quarter 9.7 M | Current Value 2.1 M | Quarterly Volatility 2.2 M |
Check Sanara Medtech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sanara Medtech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Interest Expense of 499.6 K or Total Revenue of 68.2 M, as well as many indicators such as Price To Sales Ratio of 4.97, Dividend Yield of 0.0324 or PTB Ratio of 7.97. Sanara financial statements analysis is a perfect complement when working with Sanara Medtech Valuation or Volatility modules.
Sanara | Current Deferred Revenue |
Latest Sanara Medtech's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Sanara Medtech over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Sanara Medtech's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sanara Medtech's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Sanara Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 330,493 | |
| Geometric Mean | 73,213 | |
| Coefficient Of Variation | 123.78 | |
| Mean Deviation | 352,864 | |
| Median | 13,920 | |
| Standard Deviation | 409,070 | |
| Sample Variance | 167.3B | |
| Range | 1.2M | |
| R-Value | (0.74) | |
| Mean Square Error | 81.4B | |
| R-Squared | 0.55 | |
| Significance | 0 | |
| Slope | (67,731) | |
| Total Sum of Squares | 2.3T |
Sanara Current Deferred Revenue History
About Sanara Medtech Financial Statements
Investors use fundamental indicators, such as Sanara Medtech's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Sanara Medtech's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 12 K | 11.4 K |
Currently Active Assets on Macroaxis
When determining whether Sanara Medtech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanara Medtech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanara Medtech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanara Medtech Stock:Check out the analysis of Sanara Medtech Correlation against competitors. For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanara Medtech. If investors know Sanara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanara Medtech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 9.241 | Quarterly Revenue Growth 0.352 | Return On Assets (0.05) | Return On Equity (0.20) |
The market value of Sanara Medtech is measured differently than its book value, which is the value of Sanara that is recorded on the company's balance sheet. Investors also form their own opinion of Sanara Medtech's value that differs from its market value or its book value, called intrinsic value, which is Sanara Medtech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanara Medtech's market value can be influenced by many factors that don't directly affect Sanara Medtech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanara Medtech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanara Medtech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanara Medtech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.